BREACH

Etude du Brentuximab vedotin associé à la chimiothérapie chez des patients atteints d'un Lymphome de Hodgkin stade I/II défavorable au diagnostic (phase II)

Publications 2022

Lysa 2022_LYSA_Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial

Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, Rene-Olivier Casasnovas, Anne-Claire Gac, Christophe Bonnet, Krimo Bouabdallah, Pierre Feugier, Lena Specht, Lysiane Molina, Mohamed Touati, Cecile Borel, Aspasia Stamatoullas, Emmanuelle Nicolas-Virelizier, Laurent Pascal, Pieternella Lugtenburg, Nicola Di Renzo, Thierry Vander Borght, Alexandra Traverse-Glehen, Peggy Dartigues, Martin Hutchings, Annibale Versari, Michel Meignan, Massimo Federico, Marc Andre, for the LYSA-FIL-EORTC Intergroup

doi: 10.1200/JCO.21.01281. En savoir plus

Publications 2021

Lysa 2021_LYSA_The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA

Lieselot Buedts, Iwona Wlodarska, Julio Finalet-Ferreiro, Olivier Gheysens, Luc Dehaspe, Thomas Tousseyn, Luc-Matthieu Fornecker, Julien Lazarovici, Rene-Olivier Casasnovas, Anne-Claire Gac, Christophe Bonnet, Kamal Bouabdallah, Christiane Copie-Bergman, Bettina Fabiani, Daan Dierickx, Lukas Marcelis, Joris Vermeesch, Marc Andre, Peter Vandenberghe

Blood Advances 2021 En savoir plus